Skip To Content

Clinical Connection

Thought leadership on the clinical impact on workers' compensation and auto no-fault.

Recent blog posts

February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
February 10, 2022 · Clinical Team
In October 2021, the U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride (HCl) injection - ZIMHI™ (5 mg/0.5 mL) - to treat opioid analgesic overdose. ZIMHI is designed to be administered in the muscle (intramuscular) or under the skin (subcutaneous) using a single-dose, prefilled syringe that delivers 5 mg of naloxone HCl solution. Read more...
December 09, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a new medication to prevent episodic migraine (fewer than fifteen headache days per month) on September 28, 2021. This approval allows AbbVie, Inc. to market Qulipta - a once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist - for migraine prevention. Qulipta is not indicated for the acute treatment of migraines like other oral CGRP receptor antagonists on the market, such as Ubrelvy™ (ubrogepant) and Nurtec® ODT (rimegepant). Qulipta is the second oral CGRP receptor antagonist to be approved for prevention of episodic migraine. Read more...
November 18, 2021 · Clinical Team
In April 2021, Sanofi Consumer Healthcare released a new, over-the counter (OTC) medication called Zantac 360°. Read more...
May 12, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride nasal spray – Kloxxado™ (8 mg) – on April 30, 2021. Naloxone is indicated for the emergency treatment of known or suspected opioid analgesic overdose, as manifested by respiratory and/or central nervous system (CNS) depression, for adults and pediatric patients. Read more...
May 06, 2021 · Clinical Team
Pregabalin extended-release (ER) tablets, the generic formulation of Lyrica® CR, was released on April 13, 2021, according to the U.S. Food and Drug Administration (FDA). Read more...
May 03, 2021 · Clinical Team
When injured persons receive physical therapy early in the claim, multiple industry data sources show use of opioids and other pain medications and surgeries are reduced along with time away from work. Read more...
April 28, 2021 · Clinical Team
The generic formulation of Hysingla® ER, hydrocodone bitartrate extended-release (ER) tablets, was released in March 2021 according to the U.S. Food and Drug Administration (FDA). Hysingla ER is FDA-approved for the treatment of severe pain in patients who require daily, around-the-clock, long-term opioid analgesic treatment. Read more...
     Next >>
Page 1 of 6

Subscribe today to receive our latest blogs, articles, podcasts and more.